Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Relypsa Inc (RLYP): Orbimed Advisors Trims Its Exposure to the Company

As a new filing with the Securities and Exchange Commission showed today, Samuel Isaly‘s Orbimed Advisors have trimmed its exposure to Relypsa Inc (NASDAQ:RLYP). The filing revealed that Orbimed has sold 94,000 shares in three open-market transactions at an average price of approximately $25.27 apiece. This raises the total value of the transactions to some $2.37 million. Following the sale of securities, Orbimed Advisors still owns around 8.86 million shares of Relypsa.
Relypsa Inc (NASDAQ:RLYP) is a $850 million biopharmaceutical company that is involved in development and sale of non-absorbed polymeric drugs designed for treatment of renal, cardiovascular and metablic diseases. The stock of the company remained basically flat since the beginning of the year, although it went through a significant surge during the first quarter, when it gained around 20%. The company has recently announced that it signed a multi-year agreement with Patheon, Inc. for commercial manufacturing and supply of its drug for the treatment of hyperkalemia called patiromer.
The company has also recently posted an update to its Phase 3 trial of patiromer. The results have been positive in patients with heart failure, showing a correction of hyperkalemia. The drug also showed a prevention of hyperkalemia recurrence in patients with heart-failure, as well as patients without heart failure.
Aside from Mr. Isaly, another investor bullish on Relypsa Inc (NASDAQ:RLYP) is Steven Cohen. His fund,  Point72 Asset Management, has initiated a stake in Relypsa during the second quarter of 2014, reporting ownership of 809,000 shares. In fact, Mr. Cohen’s previous fund, SAC Capital Advisors, was a shareholder of Relypsa Inc (NASDAQ:RLYP), and raised its stake by over 2,000% during the first quarter and held 198,800 shares at the end of March. Another hedge fund that owns shares of the company is Sectoral Asset Management, led by Jerome Pfund and Michael Sjostrom, which also added the company to its equity portfolio during the second quarter, reporting ownership of close to 713,000 shares in its latest 13F filing.


Disclosure: none

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.